PASSAGE BIO INC (PASG) Stock Analyst Ratings
USA - NASDAQ:PASG - US7027122099 - Common Stock
7.68 USD
+0.28 (+3.78%)
7.15 USD
-0.53 (-6.9%)
ChartMill assigns a Buy % Consensus number of 85% to PASG. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 65.54. This target is 753.32% above the current price.
PASG was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about PASG.
In the previous month the buy percentage consensus was at a similar level.
PASG was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-14 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-06-24 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-09-03 | Rodman & Renshaw | Initiate | Buy |
| 2024-05-15 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-05 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2023-11-14 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-05-12 | Raymond James | Maintains | Outperform -> Outperform |
| 2022-12-15 | Chardan Capital | Maintains | Buy |
| 2022-11-11 | Guggenheim | Maintains | Buy |
| 2022-11-11 | Citigroup | Maintains | Buy |
| 2022-11-08 | Canaccord Genuity | Initiate | Buy |
| 2022-05-17 | Raymond James | Maintains | Outperform |
| 2022-05-17 | Citigroup | Maintains | Buy |
| 2022-03-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2022-03-04 | Raymond James | Maintains | Outperform |
| 2022-01-19 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-07-01 | Raymond James | Initiate | Outperform |
| 2021-06-15 | BTIG | Initiate | Buy |
| 2021-03-08 | Chardan Capital | Maintains | Buy |
| 2021-03-04 | Goldman Sachs | Upgrade | Neutral -> Buy |
PASSAGE BIO INC / PASG FAQ
Can you provide the average price target for PASSAGE BIO INC stock?
11 analysts have analysed PASG and the average price target is 65.54 USD. This implies a price increase of 753.32% is expected in the next year compared to the current price of 7.68.
What is the consensus rating for PASG stock?
The consensus rating for PASSAGE BIO INC (PASG) is 85.4545 / 100 . This indicates that analysts generally have a positive outlook on the stock.